Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 6/2016

15.12.2015 | Original Article

Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans

verfasst von: Nathalie L. Albert, Isabel Winkelmann, Bogdana Suchorska, Vera Wenter, Christine Schmid-Tannwald, Erik Mille, Andrei Todica, Matthias Brendel, Jörg-Christian Tonn, Peter Bartenstein, Christian la Fougère

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Current guidelines for glioma imaging by positron emission tomography (PET) using the amino acid analogue O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) recommend image acquisition from 20–40 min post injection (p.i.). The maximal tumour-to-background evaluation (TBRmax) obtained in these summation images does not enable reliable differentiation between low and high grade glioma (LGG and HGG), which, however, can be achieved by dynamic 18F-FET-PET. We investigated the accuracy of tumour grading using TBRmax values at different earlier time points after tracer injection.

Methods

Three hundred and fourteen patients with histologically proven primary diagnosis of glioma (131 LGG, 183 HGG) who had undergone 40-min dynamic 18F-FET-PET scans were retrospectively evaluated. TBRmax was assessed in the standard 20–40 min summation images, as well as in summation images from 0–10 min, 5–15 min, 5–20 min, and 15–30 min p.i., and kinetic analysis was performed. TBRmax values and kinetic analysis were correlated with histological classification. ROC analyses were performed for each time frame and sensitivity, specificity, and accuracy were assessed.

Results

TBRmax values in the earlier summation images were significantly better for tumour grading (P < 0.001) when compared to standard 20–40 min scans, with best results for the early 5–15 min scan. This was due to higher TBRmax in the HGG (3.9 vs. 3.3; p < 0.001), while TBRmax remained nearly stable in the LGG (2.2 vs. 2.1). Overall, accuracy increased from 70 % in the 20–40 min analysis to 77 % in the 5–15 min images, but did not reach the accuracy of dynamic analysis (80 %).

Conclusions

Early TBRmax assessment (5–15 min p.i.) is more accurate for the differentiation between LGG and HGG than the standard static scan (20–40 min p.i.) mainly caused by the characteristic high 18F-FET uptake of HGG in the initial phase. Therefore, when dynamic 18F-FET-PET cannot be performed, early TBRmax assessment can be considered as an alternative for tumour grading.
Literatur
2.
3.
Zurück zum Zitat Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947–9.CrossRefPubMed Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947–9.CrossRefPubMed
5.
Zurück zum Zitat Bisdas S, Ritz R, Bender B, Braun C, Pfannenberg C, Reimold M, et al. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes. Investig Radiol. 2013;48:295–301. doi:10.1097/RLI.0b013e31827188d6.CrossRef Bisdas S, Ritz R, Bender B, Braun C, Pfannenberg C, Reimold M, et al. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes. Investig Radiol. 2013;48:295–301. doi:10.​1097/​RLI.​0b013e31827188d6​.CrossRef
6.
Zurück zum Zitat Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678–87. doi:10.1093/brain/awh399.CrossRefPubMed Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678–87. doi:10.​1093/​brain/​awh399.CrossRefPubMed
8.
Zurück zum Zitat Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol. 2013;15:1058–67. doi:10.1093/neuonc/not002.CrossRefPubMedPubMedCentral Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol. 2013;15:1058–67. doi:10.​1093/​neuonc/​not002.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Vees H, Senthamizhchelvan S, Miralbell R, Weber DC, Ratib O, Zaidi H. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging. 2009;36:182–93. doi:10.1007/s00259-008-0943-6.CrossRefPubMed Vees H, Senthamizhchelvan S, Miralbell R, Weber DC, Ratib O, Zaidi H. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging. 2009;36:182–93. doi:10.​1007/​s00259-008-0943-6.CrossRefPubMed
10.
Zurück zum Zitat Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004;10:7163–70. doi:10.1158/1078-0432.CCR-04-0262.CrossRefPubMed Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004;10:7163–70. doi:10.​1158/​1078-0432.​CCR-04-0262.CrossRefPubMed
11.
Zurück zum Zitat Jansen NL, Suchorska B, Schwarz SB, Eigenbrod S, Lutz J, Graute V, et al. [18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. Mol Imaging. 2013;12:137–47.PubMed Jansen NL, Suchorska B, Schwarz SB, Eigenbrod S, Lutz J, Graute V, et al. [18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. Mol Imaging. 2013;12:137–47.PubMed
12.
Zurück zum Zitat Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol. 2015. doi:10.1093/neuonc/nov088. Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol. 2015. doi:10.​1093/​neuonc/​nov088.
13.
Zurück zum Zitat Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2015;42:685–95. doi:10.1007/s00259-014-2959-4.CrossRefPubMed Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2015;42:685–95. doi:10.​1007/​s00259-014-2959-4.CrossRefPubMed
15.
Zurück zum Zitat Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40:615–35. doi:10.1007/s00259-012-2295-5.CrossRefPubMed Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40:615–35. doi:10.​1007/​s00259-012-2295-5.CrossRefPubMed
16.
Zurück zum Zitat Popperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933–42. doi:10.1007/s00259-007-0534-y.CrossRefPubMed Popperl G, Kreth FW, Mehrkens JH, Herms J, Seelos K, Koch W, et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007;34:1933–42. doi:10.​1007/​s00259-007-0534-y.CrossRefPubMed
17.
Zurück zum Zitat Langen KJ, Bartenstein P, Boecker H, Brust P, Coenen HH, Drzezga A, et al. German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids. Nuklearmedizin. 2011;50:167–73.CrossRefPubMed Langen KJ, Bartenstein P, Boecker H, Brust P, Coenen HH, Drzezga A, et al. German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids. Nuklearmedizin. 2011;50:167–73.CrossRefPubMed
18.
Zurück zum Zitat Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu Ö, Van Laere K, et al. EANM Procedure Guidelines for Brain Tumour Imaging using Labelled Amino Acid Analogues. Eur J Nucl Med Mol Imaging. 2006;33:1374–80.CrossRefPubMed Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu Ö, Van Laere K, et al. EANM Procedure Guidelines for Brain Tumour Imaging using Labelled Amino Acid Analogues. Eur J Nucl Med Mol Imaging. 2006;33:1374–80.CrossRefPubMed
19.
Zurück zum Zitat Popperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med. 2006;47:393–403.PubMed Popperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med. 2006;47:393–403.PubMed
20.
Zurück zum Zitat Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, et al. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med. 2014;55:198–203. doi:10.2967/jnumed.113.122333.CrossRefPubMed Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, et al. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med. 2014;55:198–203. doi:10.​2967/​jnumed.​113.​122333.CrossRefPubMed
23.
Zurück zum Zitat Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, et al. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med. 2013;54:2046–54. doi:10.2967/jnumed.113.123836.CrossRefPubMed Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, et al. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med. 2013;54:2046–54. doi:10.​2967/​jnumed.​113.​123836.CrossRefPubMed
24.
Zurück zum Zitat Dunkl V, Cleff C, Stoffels G, Judov N, Sarikaya-Seiwert S, Law I, et al. The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents. J Nucl Med. 2015;56:88–92. doi:10.2967/jnumed.114.148734.CrossRefPubMed Dunkl V, Cleff C, Stoffels G, Judov N, Sarikaya-Seiwert S, Law I, et al. The usefulness of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the clinical evaluation of brain tumors in children and adolescents. J Nucl Med. 2015;56:88–92. doi:10.​2967/​jnumed.​114.​148734.CrossRefPubMed
25.
Zurück zum Zitat Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A, et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med. 2011;36:841–7. doi:10.1097/RLU.0b013e3182291b40.CrossRefPubMed Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A, et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med. 2011;36:841–7. doi:10.​1097/​RLU.​0b013e3182291b40​.CrossRefPubMed
26.
27.
Zurück zum Zitat Derlon JM, Chapon F, Noel MH, Khouri S, Benali K, Petit-Taboue MC, et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med. 2000;27:778–87.CrossRefPubMed Derlon JM, Chapon F, Noel MH, Khouri S, Benali K, Petit-Taboue MC, et al. Non-invasive grading of oligodendrogliomas: correlation between in vivo metabolic pattern and histopathology. Eur J Nucl Med. 2000;27:778–87.CrossRefPubMed
28.
Zurück zum Zitat Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, et al. Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging. 2003;30:868–73. doi:10.1007/s00259-003-1148-7.CrossRefPubMed Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, et al. Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging. 2003;30:868–73. doi:10.​1007/​s00259-003-1148-7.CrossRefPubMed
29.
Zurück zum Zitat Bisdas S, Kirkpatrick M, Giglio P, Welsh C, Spampinato MV, Rumboldt Z. Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neurorad. 2009;30:681–8. doi:10.3174/ajnr.A1465.CrossRef Bisdas S, Kirkpatrick M, Giglio P, Welsh C, Spampinato MV, Rumboldt Z. Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neurorad. 2009;30:681–8. doi:10.​3174/​ajnr.​A1465.CrossRef
30.
Zurück zum Zitat Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro Oncol. 2012;14:1473–80. doi:10.1093/neuonc/nos259.CrossRefPubMedPubMedCentral Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro Oncol. 2012;14:1473–80. doi:10.​1093/​neuonc/​nos259.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Lohmann P, Herzog H, Rota Kops E, Stoffels G, Judov N, Filss C, et al. Dual-time-point O-(2-[F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas. Eur Radiol. 2015. doi:10.1007/s00330-015-3691-6.PubMed Lohmann P, Herzog H, Rota Kops E, Stoffels G, Judov N, Filss C, et al. Dual-time-point O-(2-[F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas. Eur Radiol. 2015. doi:10.​1007/​s00330-015-3691-6.PubMed
Metadaten
Titel
Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans
verfasst von
Nathalie L. Albert
Isabel Winkelmann
Bogdana Suchorska
Vera Wenter
Christine Schmid-Tannwald
Erik Mille
Andrei Todica
Matthias Brendel
Jörg-Christian Tonn
Peter Bartenstein
Christian la Fougère
Publikationsdatum
15.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3276-2

Weitere Artikel der Ausgabe 6/2016

European Journal of Nuclear Medicine and Molecular Imaging 6/2016 Zur Ausgabe